ID   HMy2.C1R
AC   CVCL_3714
AS   CVCL_E511
SY   Hmy.2 CIR; HMy2.CIR; C1R
DR   BTO; BTO:0003699
DR   CLO; CLO_0003787
DR   ATCC; CRL-1993
DR   CCRID; 3101HUMGNHu21
DR   ChEMBL-Cells; CHEMBL4295449
DR   ChEMBL-Targets; CHEMBL4296434
DR   CLS; 305126
DR   dbMHC; 48526
DR   ECACC; 94050320
DR   IHW; IHW09208
DR   IPD-IMGT/HLA; 10372
DR   Lonza; 1264
DR   PubChem_Cell_line; CVCL_3714
DR   Wikidata; Q54889982
RX   PubMed=1541831;
RX   PubMed=2784569;
RX   PubMed=3819393;
RX   PubMed=30844424;
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/c/cell-lines-detail-408.html
CC   Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC   Population: Caucasian.
CC   HLA typing: A*02:01; B*35:03; C*04:01:01; DPB1*04:01,04:02 (IPD-IMGT/HLA=10372).
CC   Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine.
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Transformant: NCIt; C44386; Gamma radiation.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
ST   Source(s): ATCC=CRL-1993
ST   Amelogenin: X
ST   CSF1PO: 6,10
ST   D13S317: 11,13
ST   D16S539: 9,13
ST   D18S51: 14,16
ST   D19S433: 14,15
ST   D21S11: 29,30
ST   D2S1338: 17
ST   D3S1358: 16
ST   D5S818: 10,13
ST   D7S820: 7,12
ST   D8S1179: 15
ST   FGA: 20,21
ST   Penta D: 10
ST   Penta E: 12
ST   TH01: 8
ST   TPOX: 8
ST   vWA: 17
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_8119 ! HMy.2 B
SX   Female
AG   33Y
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 26
//
RX   PubMed=1541831; DOI=10.4049/jimmunol.148.6.1941;
RA   Zemmour J., Little A.-M., Schendel D.J., Parham P.;
RT   "The HLA-A,B 'negative' mutant cell line C1R expresses a novel HLA-B35
RT   allele, which also has a point mutation in the translation initiation
RT   codon.";
RL   J. Immunol. 148:1941-1948(1992).
//
RX   PubMed=2784569; DOI=10.1073/pnas.86.7.2361;
RA   Storkus W.J., Alexander J., Payne J.A., Dawson J.R., Cresswell P.;
RT   "Reversal of natural killing susceptibility in target cells expressing
RT   transfected class I HLA genes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:2361-2364(1989).
//
RX   PubMed=3819393; DOI=10.4049/jimmunol.138.6.1657;
RA   Storkus W.J., Howell D.N., Salter R.D., Dawson J.R., Cresswell P.;
RT   "NK susceptibility varies inversely with target cell class I HLA
RT   antigen expression.";
RL   J. Immunol. 138:1657-1659(1987).
//
RX   PubMed=30844424; DOI=10.1016/j.humimm.2019.03.001;
RA   Creary L.E., Guerra S.G., Chong W., Brown C.J., Turner T.R.,
RA   Robinson J., Bultitude W.P., Mayor N.P., Marsh S.G.E., Saito K.,
RA   Lam K., Duke J.L., Mosbruger T.L., Ferriola D., Monos D.S., Willis A.,
RA   Askar M., Fischer G.F., Saw C.L., Ragoussis J., Petrek M.,
RA   Serra-Pages C., Juan Otero M., Stavropoulos-Giokas C., Dinou A., Ameen R.,
RA   Al Shemmari S., Spierings E., Gendzekhadze K., Morris G.P., Zhang Q.-H.,
RA   Kashi Z., Hsu S., Gangavarapu S., Mallempati K.C., Yamamoto F.,
RA   Osoegawa K., Vayntrub T., Chang C.-J., Hansen J.A.,
RA   Fernandez-Vina M.A.;
RT   "Next-generation HLA typing of 382 International Histocompatibility
RT   Working Group reference B-lymphoblastoid cell lines: report from the
RT   17th International HLA and Immunogenetics Workshop.";
RL   Hum. Immunol. 80:449-460(2019).
//